Boston Scientific agrees to acquire Devoro Medical

Boston Scientific has agreed to acquire Devoro Medical, developer of the WOLF Thrombectomy Platform. The non-console and lytic-free WOLF technology targets and rapidly captures blood clots using finger-like prongs that retrieve and remove thrombi in the arterial and venous systems.

Jeff Mirviss, executive vice president and president, peripheral interventions, Boston Scientific, said: "The addition of the WOLF platform advances our efforts to ensure physicians have the right tools to improve procedural efficiencies. Clot management remains a core focus of our business, and upon commercialisation, this highly differentiated technology will complement and expand our offerings to a full suite of interventional strategies for thromboemboli, which also includes the EkoSonic Endovascular System (EKOS) and the AngioJet Thrombectomy System."

Boston Scientific has been a strategic investor in Devoro Medical since 2019 and currently holds an equity stake of approximately 16%. As a result, the transaction consists of an upfront payment of approximately $269 million for the 84% stake not yet owned and up to $67 million upon achievement of certain clinical and regulatory milestones.

Michael R. Jaff, chief medical officer and vice president of clinical affairs, technology and innovation, peripheral interventions, Boston Scientific, said: "The WOLF platform is a compelling new option for physicians performing thrombectomy procedures and, importantly, it is designed to target and remove clots without damaging blood vessels, while also minimising blood-loss, which may improve outcomes. We look forward to accelerating the progress of this platform technology so that we help patients who are dealing with these common, yet challenging health conditions."